Congruence Therapeutics has announced the closing of a $39.5 million financing to support the advancement of its pipeline of small molecule correctors targeting diseases caused by protein misfolding. The financing round was co-led by Dimension and OrbiMed, with participation from Amplitude Ventures, FSTQ, Lumira Ventures, Investissement Québec, BDC Capital, Driehaus Capital Management, and Silver Arc.
The company will use the proceeds to advance its lead program, CGX-926, which is currently in a Phase 1/1b clinical trial for MC4R-deficient genetic obesity. The study is evaluating the therapy in both healthy subjects and patients with the condition. In parallel, Congruence plans to complete IND-enabling activities for two additional programs targeting…